Back to top
more

Seer (SEER)

(Delayed Data from NSDQ)

$2.30 USD

2.30
692,887

+0.29 (14.43%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $2.22 -0.08 (-3.48%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of +15.38% and +8.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Makes Seer, Inc. (SEER) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Seer, Inc. (SEER) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of 8.11% and 26.28%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 50% and 43.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 7.07% and 5.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AnaptysBio (ANAB) delivered earnings and revenue surprises of 1.54% and 52.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

After Plunging -16.59% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

After Plunging -16.81% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)

by Zacks Equity Research

Seer (SEER) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of 15% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Nilanshi Mukherjee headshot

QuantumSi Set to Report Q4 Earnings: Buy, Sell or Hold the Stock?

by Nilanshi Mukherjee

QSI's fourth-quarter performance is expected to have benefited from year-end capital spending and new product launches despite competition and stretched valuation.

Zacks Equity Research

Repligen (RGEN) Beats Q4 Earnings Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 7.32% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Illumina (ILMN) Q4 Earnings Miss Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of -6.52% and 2.64%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of -17.24% and 19.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of 2.78% and 7.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 400% and 15.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of -3.23% and 13.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of 20% and 4.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Seer, Inc. (SEER), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of 13.16% and 5.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of 2.63% and 25.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of -2.70% and 1.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

NeoGenomics (NEO) delivered earnings and revenue surprises of 35.71% and 8.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?